Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis | Zendy

Nan Chen | Zendy; ChuanMing Hao | Zendy; Xiaomei Peng | Zendy; Hongli Lin | Zendy; Aiping Yin | Zendy; Hao Li | Zendy; Ye Tao | Zendy; Xinling Liang | Zendy; Zhengrong Liu | Zendy; Xing Changying | Zendy; Jianghua Chen | Zendy; Laimin Luo | Zendy; Li Zuo | Zendy; Yunhua Liao | Zendy; BiCheng Liu | Zendy; Robert Leong | Zendy; Chunrong Wang | Zendy; Cameron Liu | Zendy; Thomas B. Neff | Zendy; Lynda A. Szczech | Zendy; Kin-Hung P. Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Author(s) -

Nan Chen,

ChuanMing Hao,

Xiaomei Peng,

Hongli Lin,

Aiping Yin,

Hao Li,

Ye Tao,

Xinling Liang,

Zhengrong Liu,

Xing Changying,

Jianghua Chen,

Laimin Luo,

Li Zuo,

Yunhua Liao,

BiCheng Liu,

Robert Leong,

Chunrong Wang,

Cameron Liu,

Thomas B. Neff,

Lynda A. Szczech,

Kin-Hung P. Yu

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1813599

Subject(s) - anemia , dialysis , medicine , kidney disease , intensive care medicine , disease

Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research